MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib

Samankaltaisia teoksia

• DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
  Tekijä: Gupta, A, et al.
  Julkaistu: (2013)
• AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
  Tekijä: Dummer, R, et al.
  Julkaistu: (2008)
• Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
  Tekijä: Jin-Hang Gao, et al.
  Julkaistu: (2022-03-01)
• Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
  Tekijä: Takahashi, O, et al.
  Julkaistu: (2012)
• Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis
  Tekijä: Takahashi, O, et al.
  Julkaistu: (2012)